The main protease and RNA-dependent RNA polymerase are two prime targets for SARS-CoV-2.
Biochem Biophys Res Commun
; 538: 63-71, 2021 01 29.
Article
in English
| MEDLINE | ID: covidwho-1125596
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses an unprecedented global health crisis. It is particularly urgent to develop clinically effective therapies to contain the pandemic. The main protease (Mpro) and the RNA-dependent RNA polymerase (RdRP), which are responsible for the viral polyprotein proteolytic process and viral genome replication and transcription, respectively, are two attractive drug targets for SARS-CoV-2. This review summarizes up-to-date progress in the structural and pharmacological aspects of those two key targets above. Different classes of inhibitors individually targeting Mpro and RdRP are discussed, which could promote drug development to treat SARS-CoV-2 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Enzyme Inhibitors
/
Coronavirus Protease Inhibitors
/
Coronavirus RNA-Dependent RNA Polymerase
/
Coronavirus 3C Proteases
/
SARS-CoV-2
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Biochem Biophys Res Commun
Year:
2021
Document Type:
Article
Affiliation country:
J.bbrc.2020.10.091
Similar
MEDLINE
...
LILACS
LIS